This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
HeadlineMEDTECH

AI Arrhythmia Alert Patch CardioSense Receives FDA Approval: 24-Hour Continuous Monitoring Replaces Traditional Holter

Medical tech company AliveCor's AI arrhythmia alert patch CardioSense received FDA 510(k) approval. Worn continuously for up to 14 days, the AI algorithm achieves 99.1% sensitivity in detecting atrial fibrillation, poised to replace traditional Holter monitoring devices that require frequent electrode changes.

Full Article

On May 13, 2028, medical technology company AliveCor announced that its AI arrhythmia alert patch CardioSense received FDA 510(k) clearance. This single-use patch can be worn continuously for 14 days, with built-in AI algorithms that analyze ECG signals in real-time and alert for arrhythmia events including atrial fibrillation.

CardioSense resembles a large adhesive bandage, applied to the left chest area. The device integrates three flexible dry electrodes, a low-power ECG signal processor, and a Bluetooth communication module. Unlike traditional Holter monitors that require daily electrode changes and carrying a recorder, CardioSense needs no maintenance—wearers can shower and exercise normally.

AliveCor CEO Priya Abani said CardioSense's AI algorithm performed excellently in a clinical trial of 12,000 subjects: 99.1% sensitivity for atrial fibrillation, 98.3% specificity, and 97.6% sensitivity for ventricular premature beats. "This means the vast majority of arrhythmia events are accurately captured while false alarms remain at acceptable levels."

FDA cardiovascular device division director Bram Zuckerman said in the approval statement: "CardioSense represents an important advance in cardiac monitoring. Fourteen days of unobtrusive monitoring will significantly improve arrhythmia detection rates, especially for paroxysmal events that are difficult to capture during short monitoring periods."

For the Chinese market, AliveCor has partnered with Lepu Medical to introduce CardioSense to China in Q4 2028. Lepu Medical chairman Pu Zhongjie said China has over 20 million atrial fibrillation patients, approximately one-third of whom are undiagnosed. "CardioSense's convenience could significantly improve screening coverage."

However, some physicians have expressed concern about potential "overdiagnosis" from continuous cardiac monitoring. Ma Changsheng, director of cardiology at Beijing Anzhen Hospital, noted that some clinically insignificant cardiac rhythm abnormalities might be captured by CardioSense, leading to unnecessary visits and anxiety. "It's good that technology can detect more information, but both doctors and patients need to learn how to interpret it correctly."